Iacovelli R.; Ciccarese C.; Maruzzo M.; Atzori F.; Galli L.; Scagliarini S.; Massari F.; Verzoni E.; Cannella A.; Maratta M.G.; Caserta C.; Bimbatti D.; Deppieri F.M.; Dessi M.; Paolieri F.; Riccardi F.; Bracarda S.; De Giorgi U.; Basso U.; Tortora G.; Procopio G., Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 498 - 498.e9 [Scientific article]
Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D., Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis, «CURRENT ONCOLOGY», 2022, 29, pp. 5846 - 5854 [Scientific article]Open Access
Santoni M.; Molina-Cerrillo J.; Massari F.; Montironi R.; Grande E., Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study, «EUROPEAN UROLOGY», 2022, 81, pp. 623 - 624 [Scientific article]
Righini M.; Mollica V.; Rizzo A.; La Manna G.; Massari F., Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 4373 , pp. 1 - 17 [Scientific article]Open Access
Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Massari F., Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials, «FUTURE ONCOLOGY», 2022, 18, pp. 625 - 634 [Scientific article]
Orsatti, Agnese; Sirolli, Maria; Ambrosi, Francesca; Franceschini, Tania; Giunchi, Francesca; Franchini, Eugenia; Grillini, Marco; Massari, Francesco; Mollica, Veronica; Bianchi, Federico Mineo; Colecchia, Maurizio; Fiorentino, Michelangelo; Ricci, Costantino, SOX2 and PRAME in the "reprogramming" of seminoma cells, «PATHOLOGY, RESEARCH AND PRACTICE», 2022, 238, Article number: 154044 , pp. 237 - 237 [Scientific article]
Santoni M.; Massari F.; Matrana M.R.; Basso U.; De Giorgi U.; Aurilio G.; Buti S.; Incorvaia L.; Rizzo M.; Martignetti A.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Porta C.; Battelli N., Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma, «EUROPEAN JOURNAL OF CANCER», 2022, 172, pp. 191 - 198 [Scientific article]
Santoni M.; Monteiro F.S.M.; Massari F.; Abahssain H.; Aurilio G.; Molina-Cerrillo J.; Myint Z.W.; Zabalza I.O.; Battelli N.; Grande E., Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 176, Article number: 103731 , pp. 103731 - 103738 [Scientific article]
Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [Scientific article]Open Access
Nuvola G.; Rizzo A.; Mollica V.; Massari F., The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?, «IMMUNOTHERAPY», 2022, 14, pp. 171 - 174 [Scientific article]
Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F., The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis, «JOURNAL OF PERSONALIZED MEDICINE», 2022, 12, Article number: 842 , pp. 1 - 8 [Scientific article]Open Access
Santoni M.; Rizzo A.; Mollica V.; Matrana M.R.; Rosellini M.; Faloppi L.; Marchetti A.; Battelli N.; Massari F., The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 170, Article number: 103596 , pp. 103596 - 103603 [Scientific article]
Man Y.-G.; Mannion C.; Jewett A.; Hsiao Y.-H.; Liu A.; Semczuk A.; Zarogoulidis P.; Gapeev A.B.; Cimadamore A.; Lee P.; Lopez-Beltran A.; Montironi R.; Massari F.; Lu X.; Cheng L., The most effective but largely ignored target for prostate cancer early detection and intervention, «JOURNAL OF CANCER», 2022, 13, pp. 3463 - 3475 [Scientific article]Open Access
Rebuzzi S.E.; Signori A.; Stellato M.; Santini D.; Maruzzo M.; De Giorgi U.; Pedrazzoli P.; Galli L.; Zucali P.A.; Fantinel E.; Carella C.; Procopio G.; Milella M.; Boccardo F.; Fratino L.; Sabbatini R.; Ricotta R.; Panni S.; Massari F.; Soraru M.; Santoni M.; Cortellini A.; Prati V.; Soto Parra H.; Atzori F.; Di Napoli M.; Caffo O.; Messina M.; Morelli F.; Prati G.; Nole F.; Vignani F.; Cavo A.; Roviello G.; Llaja Obispo M.A.; Porta C.; Buti S.; Fornarini G.; Banna G.L., The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 955501 , pp. 1 - 15 [Scientific article]Open Access
Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M., Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy, «CANCER MANAGEMENT AND RESEARCH», 2022, 14, pp. 1945 - 1960 [Scientific article]Open Access
